RecruitingPhase 2NCT03290534

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®


Sponsor

CivaTech Oncology

Enrollment

40 participants

Start Date

Mar 13, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.


Eligibility

Min Age: 18 Years

Inclusion Criteria10

  • Subject signed inform consent
  • Suspected or proven non-small cell lung cancer (NSCLC) in the upper lobes of the left or right lung
  • Pre-operative criteria
  • Lung nodule suspicious for NSCLC
  • Mass ≤ 7 cm in maximum diameter by CT scan of the chest and upper abdomen
  • Clinical stage I or Clinical stage II
  • Not pregnant or nursing
  • Negative pregnancy test in premenopausal women
  • Fertile patients must use effective contraception
  • More than 5 years since prior invasive malignancy unless non melanoma skin cancer or in-situ cancer

Exclusion Criteria1

  • \-

Interventions

DEVICECivaSheet

implanting CivaSheet for localized radiation dose delivery


Locations(1)

NYU Langone Health

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03290534


Related Trials